Deutsche Bank raised the firm’s price target on Cellebrite (CLBT) to $24 from $22 and keeps a Buy rating on the shares as part of a 2025 software sector outlook. Software will outperform in 2025 as a result of improving fundamentals, positive estimate revisions and modest multiple expansion over the course of the year, the analyst tells investors in a research note. The firm expects improving demand trends and artificial intelligence optimism to more than offset “slow-but-ramping” generative AI adoption, elevated capex, and an ongoing scaling-laws debate.
Stay Ahead of the Market:
- Discover outperforming stocks and invest smarter with Top Smart Score Stocks
- Filter, analyze, and streamline your search for investment opportunities using Tipranks' Stock Screener
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CLBT:
- Cellebrite Strengthens Board with New Appointments for 2025 Growth
- Cellebrite appoints Capellas to board of directors, updates board positions
- Cellebrite price target raised to $24 from $22 at JPMorgan
- Cellebrite price target raised to $25 from $23 at TD Cowen
- Cellebrite management to meet with Craig-Hallum